Risvutatug rezetecan: all 23 studies that test it
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingNCT07802704Phase 3
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingNCT07736612Phase 1/2
- A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT07621601Phase 3
- A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)RecruitingNCT07602855Phase 1/2
- A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNot yet recruitingNCT07464327Phase 3
- HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07462923Phase 1
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain MetastasesRecruitingNCT07268053Early Phase 1
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingNCT07230106Phase 2
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid TumorsRecruitingNCT07186452Phase 1
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingNCT07115446Phase 1
- A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingNCT07099898Phase 3
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)RecruitingNCT06885034Phase 1/2
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Phase 1
- A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06526624Phase 3
- HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsRecruitingNCT06112704Phase 2
- ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06007729Phase 2
- ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid TumorsRecruitingNCT06001255Phase 2
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Phase 2
- Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedNCT06935409Phase 3
- ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerCompletedNCT06498479Phase 3
- ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT06052423Phase 2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid TumorsStatus unknownNCT05276609Phase 1